GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kite Pharma Inc (NAS:KITE) » Definitions » EPS without NRI

Kite Pharma (Kite Pharma) EPS without NRI : $-6.91 (TTM As of Jun. 2017)


View and export this data going back to 2014. Start your Free Trial

What is Kite Pharma EPS without NRI?

Kite Pharma's earnings per share without non-recurring items for the three months ended in Jun. 2017 was $-1.94. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2017 was $-6.91.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Kite Pharma's EPS without NRI or its related term are showing as below:

KITE's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 5.45
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Kite Pharma's EPS (Diluted) for the three months ended in Jun. 2017 was $-1.94. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2017 was $-6.91.

Kite Pharma's EPS (Basic) for the three months ended in Jun. 2017 was $-1.94. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2017 was $-6.91.


Kite Pharma EPS without NRI Historical Data

The historical data trend for Kite Pharma's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kite Pharma EPS without NRI Chart

Kite Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16
EPS without NRI
- -0.22 -1.91 -2.33 -5.46

Kite Pharma Quarterly Data
Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.31 -1.49 -1.74 -1.74 -1.94

Competitive Comparison of Kite Pharma's EPS without NRI

For the Biotechnology subindustry, Kite Pharma's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kite Pharma's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kite Pharma's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Kite Pharma's PE Ratio without NRI falls into.



Kite Pharma EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kite Pharma  (NAS:KITE) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Kite Pharma EPS without NRI Related Terms

Thank you for viewing the detailed overview of Kite Pharma's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Kite Pharma (Kite Pharma) Business Description

Traded in Other Exchanges
N/A
Address
Kite Pharma is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products. In partnership with the National Cancer Institute through a cooperative research and development agreement, Kite is advancing a pipeline of proprietary product candidates, both chimeric antigen receptor and T-cell receptor products, targeting a wide range of cancer indications. The company also has a strategic collaboration with Amgen to develop and commercialize next-generation CAR-T therapies.
Executives
Jonathan M Peacock director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
David Bonderman director 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Franz B Humer director 388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10013
Shawn Tomasello officer: Chief Commercial Officer C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Ian T Clark director SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Farah Champsi director ONE EMBARCADERO CENTER SUITE 3700, SAN FRANCISCO CA 94111
Helen Susan Kim officer: EVP, Business Development 3832 BAY CENTER PLACE, HAYWARD CA 94545
Timothy L. Moore officer: EVP, Technical Operations C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Ran Nussbaum director C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Cynthia M Butitta officer: Chief Operating Officer 3165 PORTER DRIVE, PALO ALTO CA 94304
Owen N. Witte director C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
David D Chang officer: EVP, R&D, Chief Medical Off. C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Joshua A Kazam director 689 5TH AVENUE, 12TH FLOOR, NEW YORK NY 10022
Arie Belldegrun director, officer: Chairman, President and CEO UCLA SCHOOL OF MEDICINE, 10833 LE CONTE 66-118 CHS BOX 951738, LOS ANGELES CA 9095-1738
Margo R Roberts officer: Chief Scientific Officer 2225 COLORADO AVENUE, SANTA MONICA CA 90404

Kite Pharma (Kite Pharma) Headlines

From GuruFocus

Andreas Halvorsen Nearly Quadruples Stake in Kite Pharma

By David Goodloe David Goodloe 10-06-2015

Multiple Companies Achieve Yearly Highs

By yifan900 yifan900 10-03-2017

Mario Gabelli Exits Kite Pharma, Trims Time Warner

By Tiziano Frateschi Tiziano Frateschi 02-07-2018

Mario Gabelli's Top 5 New Buys for the 3rd Quarter

By Sydnee Gatewood Sydnee Gatewood 11-03-2017